Trials / Active Not Recruiting
Active Not RecruitingNCT06408311
Safety of ENC-201-CED ENCRT
A Safety and Tolerability Study of ENC=201-CED in Participants With Type 1 Diabetes Receiving Islet Infusion
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Encellin · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety and tolerability of ENC-201-CED in a subcutaneous space in patients with Type I diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | ENC-201-CED hPI | macro-encapsulated human primary islets |
Timeline
- Start date
- 2024-05-01
- Primary completion
- 2026-07-31
- Completion
- 2026-10-30
- First posted
- 2024-05-10
- Last updated
- 2026-03-11
Locations
2 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT06408311. Inclusion in this directory is not an endorsement.